Oligonucleotide therapies are among the most promising biological therapeutics. They target disease at a different stage of ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

OnCusp Therapeutics receives US FDA fast track designation for CUSP06 for treatment of platinum-resistant ovarian cancer: Princeton, New Jersey Saturday, February 15, 2025, 15:00 ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Scientists have uncovered a blood-based molecular signature that can predict vaccine durability. Could this change ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...

Work at Exelixis Inc. has led to the development of antibody-drug conjugates (ADCs) comprising antibodies targeting interleukin-13 receptor subunit α2 (IL-13RA2, IL-13R-α2) covalently linked to a ...

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...